文献速递前列腺癌

靶向微波消融治疗局限性前列腺癌(VIOLETTE试验):前瞻性多中心研究

Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study.
PubMed 文献 · BJU Int · 2026-03-11

VIOLETTE是一项前瞻性II期多中心欧洲研究,评估基于器官追踪融合引导的靶向微波消融(TMA)在中危前列腺癌患者中的肿瘤学结局。共76例患者接受治疗,66例完成12个月随访,主要终点12个月治疗区内无临床显著前列腺癌(csPCa)率为81%,达到主要终点。研究认为TMA是安全有效的局灶治疗方式,但性功能和射精功能评分显著下降。

要点

  • 12个月治疗区内无csPCa率为81%,达到主要终点。
  • 3例患者报告5起严重不良事件,4例(5.2%)需根治性治疗。
  • 性功能评分下降2.5分、射精功能评分下降1分(均P<0.001),排尿功能稳定。

核心结论

  • 基于器官追踪融合技术的靶向微波消融对局限性中危前列腺癌似乎是安全有效的局灶治疗,12个月治疗区内无csPCa率达81%。

研究设计与样本

  • 前瞻性II期多中心欧洲研究(VIOLETTE,NCT04582656),共76例患者接受治疗,66例(87%)完成12个月随访。

主要发现

  • 6个月时6例经MRI阳性确认后检出csPCa,其中4例位于治疗区内。
  • 12个月时新增15例csPCa,其中9例为治疗区内复发,治疗区内无csPCa率为81%。
  • 3例患者报告5起严重不良事件;性功能评分下降2.5分(P<0.001),射精功能评分下降1分(P<0.001),排尿功能稳定。
  • 12个月时4例(5.2%)患者需要根治性治疗。

关键数值与推荐

  • 入组标准:PSA<20 ng/mL、单发MRI可见病灶≤15 mm、MRI靶向活检ISUP分级组2、临床T分期≤2。
  • 主要终点:12个月时治疗区内无ISUP分级组≥2的临床显著前列腺癌。

临床怎么用

  • 对于严格筛选的中危局限性前列腺癌患者,可考虑将靶向微波消融作为局灶治疗选项。
  • 治疗前需告知患者性功能和射精功能可能显著下降,但排尿功能预期稳定。
  • 术后需通过MRI和活检进行严密随访,监测治疗区内复发。

局限性

  • 单臂II期研究,样本量有限(76例),随访仅12个月。
  • 原文未报告长期肿瘤学结局和随机对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the oncological outcomes of targeted microwave ablation (TMA) using organ-based tracking (OBT) Fusion® via KOELIS Trinity® (KOELIS, Meylan, France) in men with intermediate-risk prostate cancer (PCa): the VIOLETTE trial (ClinicalTrials.gov identifier: NCT04582656) PATIENTS AND METHOD: In this prospective phase II, multicentre European study, men with a prostate-specific antigen (PSA) level <20 ng/mL, a single magnetic resonance imaging (MRI)-visible lesion ≤15 mm, International Society of Urological Pathology (ISUP) Grade Group 2 on MRI-targeted biopsy, and clinical T stage ≤2, were enrolled. The microwave applicator was placed using OBT Fusion guidance, either transperineally or transrectally. The primary endpoint was the absence of clinically significant PCa (csPCa), defined as ISUP Grade Group ≥2, within the treated area at 12 months. Secondary endpoints included safety, functional outcomes using validated measures, and the need for subsequent radical treatment. RESULTS: A total of 76 patients were treated across six centres with 66 (87%) completing the 12-month follow-up. At 6 months, six patients had csPCa after positive MRI control, including four within the treated area. At 12 months, csPCa was detected in 15 additional patients, including nine in-field recurrences, yielding an 81% in-field csPCa-free rate. Five serious adverse events in three patients were reported. Sexual (-2.5 points; P < 0.001) and ejaculatory (-1 points; P < 0.001) scores decreased significantly, whereas urinary function remained stable. Radical treatment was required in four (5.2%) patients at 12 months. CONCLUSION: Targeted microwave ablation using OBT Fusion technology appears to be a safe and effective focal therapy procedure for localised intermediate-risk PCa. The VIOLETTE trial achieved its primary endpoint, with 81% patients free of in-field csPCa at 12 months.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Delongchamps NB, Peltier A, Potiron E, et al. Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study. BJU Int. 2026. PMID: 41810596. doi:10.1111/bju.70220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。